drugset / Trial / NCT02713477

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

NCT02713477

Phase 1 Completed 20 enrolled Sanofi
RandomizedCrossoverOpen-labelTreatment

Summary

Primary Objective: To assess the postprandial glucodynamic response to 2 doses of insulin glargine/lixisenatide fixed-ratio combination compared to placebo in Japanese patients with type 2 diabetes mellitus (T2DM). Secondary Objectives: * To assess the pharmacokinetics (PK) of lixisenatide following administration of 2 different doses of insulin glargine/lixisenatide fixed-ratio combination in Japanese patients with T2DM. * To assess the postprandial glucodynamic response to insulin glargine/lixisenatide fixed-ratio combination compared to insulin glargine alone in Japanese patients with T2DM. * To assess the safety and tolerability of insulin glargine/lixisenatide fixed-ratio combination in Japanese patients with T2DM.

Timeline

Start
2016-04
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lixisenatide Peptide 5 ug Subcutaneous
Subject Lixisenatide Peptide 10 ug Subcutaneous
Subject insulin glargine Protein / enzyme biologic 5 iu Subcutaneous
Subject insulin glargine Protein / enzyme biologic 10 iu Subcutaneous